Table 4.
Results of immunotherapy in patients with PD-L1 CPS ≥10.
| Treatment | Sample size | Treatment line | OS (m) | PFS (m) |
|---|---|---|---|---|
| Pembrolizumab1 | 92 | 1 | 17.4 (9.1–23.1) | 2.9 (1.6–5.4) |
| Pembrolizumab2 | 46 | 1 | 7.9 (5.8–11.1) | 2.1 |
| Pembrolizumab3 | 53 | 2 | 10.4 (5.9–17.3) | 2.7 |
| Pembrolizumab+FC/XP | 99 | 1 | 12.3 (9.5–14.8) | NA |
| Pembrolizumab+SOX | 31 | 1 | NA | 8.1 (5.5–NR) |
NA, not available; OS, overall survival; PFS, progression-free survival; FC, 5-FU plus cisplatin; XP, capecitabine plus cisplatin; SOX, S-1 plus oxaliplatin.
1Results from KEYNOTE-062.
2Results from KEYNOTE-059 cohort 1.
3Results from KEYNOTE-061.